Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Raised by Checchi Capital Advisers LLC

Checchi Capital Advisers LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.8% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,616 shares of the biopharmaceutical company’s stock after purchasing an additional 836 shares during the period. Checchi Capital Advisers LLC’s holdings in Gilead Sciences were worth $895,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the company. Cetera Investment Advisers raised its stake in Gilead Sciences by 9.2% during the 1st quarter. Cetera Investment Advisers now owns 57,967 shares of the biopharmaceutical company’s stock valued at $3,446,000 after acquiring an additional 4,877 shares in the last quarter. Baird Financial Group Inc. boosted its holdings in shares of Gilead Sciences by 3.9% in the first quarter. Baird Financial Group Inc. now owns 448,409 shares of the biopharmaceutical company’s stock valued at $26,660,000 after acquiring an additional 16,643 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its stake in shares of Gilead Sciences by 44.3% during the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 8,642 shares of the biopharmaceutical company’s stock valued at $514,000 after acquiring an additional 2,654 shares during the period. Donaldson Capital Management LLC raised its holdings in Gilead Sciences by 12.5% during the first quarter. Donaldson Capital Management LLC now owns 5,763 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 641 shares in the last quarter. Finally, Ergoteles LLC acquired a new position in shares of Gilead Sciences during the 1st quarter valued at $2,304,000. 82.33% of the stock is currently owned by institutional investors.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 1,501 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total value of $115,561.99. Following the completion of the sale, the insider now directly owns 70,130 shares in the company, valued at $5,399,308.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Andrew D. Dickinson sold 5,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 17th. The shares were sold at an average price of $80.00, for a total value of $400,000.00. Following the transaction, the chief financial officer now owns 104,003 shares in the company, valued at approximately $8,320,240. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 1,501 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total transaction of $115,561.99. Following the sale, the insider now owns 70,130 shares of the company’s stock, valued at $5,399,308.70. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Piper Sandler dropped their price target on shares of Gilead Sciences from $105.00 to $100.00 and set an “overweight” rating on the stock in a research report on Monday, July 24th. HSBC initiated coverage on shares of Gilead Sciences in a research note on Wednesday, September 6th. They set a “reduce” rating and a $71.00 target price for the company. UBS Group decreased their price target on shares of Gilead Sciences from $85.00 to $84.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 8th. Royal Bank of Canada decreased their target price on Gilead Sciences from $78.00 to $77.00 and set a “sector perform” rating on the stock in a report on Tuesday. Finally, Leerink Partnrs reaffirmed a “market perform” rating on shares of Gilead Sciences in a report on Wednesday, October 11th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Hold” and an average target price of $88.22.

Gilead Sciences Stock Down 0.7 %

GILD stock opened at $74.52 on Friday. The company has a 50 day moving average of $76.84 and a two-hundred day moving average of $77.34. The company has a market cap of $92.85 billion, a price-to-earnings ratio of 15.99, a PEG ratio of 1.00 and a beta of 0.32. Gilead Sciences, Inc. has a 12-month low of $72.87 and a 12-month high of $89.74. The company has a quick ratio of 1.20, a current ratio of 1.34 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.38. The firm had revenue of $7.05 billion for the quarter, compared to the consensus estimate of $6.81 billion. Gilead Sciences had a return on equity of 39.30% and a net margin of 21.45%. The business’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.90 earnings per share. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 6.76 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be given a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 4.03%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is 64.38%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.